Research Announcement- Denosumab Clinical Study for Children with OI
Date: November 30, 2017
Amgen is sponsoring a multicenter clinical trial to study the safety and efficacy of the investigational drug Denosumab on bone mineral and fracture occurrence in children who have OI. Currently the study is open to eligible children ages 7-17 who have a diagnosis of OI Type I through IV. In late January 2018 Amgen anticipates opening the study to eligible children 2-6 years of age. The study has 38 sites are participating in this clinical research study in the following countries: Australia, Belgium, Bulgaria, Canada, Czech Republic, France, Germany, Hungary, Italy, Poland, Spain, United Kingdom and, United States. For more information and a complete list of study locations, visit their Clinical Trials website. If you have any additional questions, please contact the Amgen Call Center at +1 (866) 572-6436. Their Customer Service Representative will be able to find a site near you and provide you with the site study contacts; who will tell you more about the clinical research Study.